)
Proteomics International to collaborate with University of Melbourne and Royal Women’s Hospital to develop a test for endometriosis
The collaboration aims to build on a Proteomics study that identified protein ‘fingerprints’ in the blood - known as biomarkers - that could be used to test for endometriosis. The collaboration consists of two phases: validation of existing biomarkers and subsequent discovery of new biomarkers.
Proteomics International Laboratories Ltd (ASX:PIQ) has signed a research agreement with the University of Melbourne and the Royal Women’s Hospital to collaborate to develop a non-invasive simple blood test for endometriosis.
The partnership aims to develop the world’s first blood test for the painful condition, which affects one in nine women and costs Australia $9.7 billion each year.
2021-07-23 by Proactive Australia
Proteomics International Laboratories Ltd (ASX:PIQ) has engaged global life science company Abcam plc (LON:ABC)(OTCMKTS:ABCZF) to manufacture reagents for the immunoassay version of its PromarkerD predictive blood test for the early detection of kidney disease in patients with type 2 diabetes.
Abcam is a leader in the supply of life science research tools and reagents, including supply to those companies developing and marketing diagnostic solutions around the world.
Under the terms of the commercial fee-for-service agreement, Abcam will produce the specialist reagents including synthetic protein standards and antibodies, required for the immunoassay version of the PromarkerD test.